Role of macrolide therapy in chronic obstructive pulmonary disease

International Journal of COPD

Volumn 3, Issue 3, 2008, Pages 331-350

  Martinez, Fernando J ^a   Curtis, Jeffrey L ^a,b   Albert, Richard ^c  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^b VA ANN ARBOR HEALTHCARE SYSTEM   (United States)

^c DENVER HEALTH MEDICAL CENTER   (United States)

Author keywords

AECOPD; Antibiotics; Macrolide therapy

Indexed keywords

AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; AZITHROMYCIN; CEFACLOR; CLARITHROMYCIN; ERYTHROMYCIN; GEMIFLOXACIN; JOSAMYCIN; LEVOFLOXACIN; MACROLIDE; MOXIFLOXACIN; OFLOXACIN; PLACEBO; RIBOFLAVIN; ROKITAMYCIN; ROXITHROMYCIN; TROLEANDOMYCIN;

ANTIBACTERIAL ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ASTHMA; BRONCHIECTASIS; CHRONIC DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; CYSTIC FIBROSIS; DIFFUSE PANBRONCHIOLITIS; DISEASE EXACERBATION; DRUG BIOAVAILABILITY; DRUG MECHANISM; DRUG RESPONSE; DRUG STRUCTURE; HUMAN; IMMUNOMODULATION; INFLAMMATORY DISEASE; LOW DRUG DOSE; LUNG INFECTION; PATHOGENESIS; PNEUMONIA; RESPIRATORY TRACT INFLAMMATION; REVIEW;

ANTI-BACTERIAL AGENTS; ASTHMA; AZITHROMYCIN; BRONCHIECTASIS; BRONCHIOLITIS; CYSTIC FIBROSIS; DISEASE PROGRESSION; HUMANS; MACROLIDES; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUALITY OF LIFE;

EID: 54949097336     PISSN: 11769106     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (276)

1. Aaron SD, Angel JB, Lunau M, et al. 2001. Granulocyte inflammatory markers and airway infection during acute exacerbation of chronic obstructive pulmonary disease. Am J Respir Crit Care Med, 163:349-55.
2. Aberg JA, Wong MK, Flamm R, et al. 2001. Presence of macrolide resistance in respiratory flora of HIV-infected patients receiving either clarithromycin or azithromycin for Mycobacterium avium complex prophylaxis. HIV Clin Trials, 2:453-9.
3. Adachi T, Motojima S, Hirata A, et al. 1996. Eosinophil apoptosis caused by theophylline, glucocorticoids, and macrolides after stimulation with IL-5. J Allergy Clin Immunol, 98:S207-15.
4. Agen C, Danesi R, Blandizzi C, et al. 1993. Macrolide antiboitics as antiinflammatory agents: roxithromycin in an unexpected role. Agents Actions, 38:85-90.
5. Agusti AGN. 2005. COPD, a multicomponent disease: implicationis for management. Respir Med, 99:670-82.
6. Akira M, Kitatani F, Lee YS, et al. 1988. Diffuse panbronchiolitis: evaluation with high-resolution CT. Radiology, 168:43-8.
7. Allegra L, Blasi F, de Bernardi B, et al. 2001. Antibiotic treatment and baseline severity or disease in acute exacerbations of chronic bronchitis: a re-evaluation of previously published data of a placebo-controlled randomized study. Pulm Pharmacol Therapeut, 14:149-55.
8. Allegra L, Blasi F, Diano PL, et al. 2005. Sputum color as a marker of acute bacterial exacerbations of chronic obstructive pulmonary disease. Respir Med, 99:742-7.
9. Amayasu H, Yoshida S, Ebana S, et al. 2000. Clarithromycin suppresses bronchial hyperresponsiveness associated with eosinophilic inflammation in patients with asthma. Ann Allergy Asthma Immunol, 84:594-8.
10. Amin K, Ekberg-Jansson A, Lofdahl CG, et al. 2003. Relationship between inflammatory cells and structural changes in the lungs of asymptomatic and never smokers: a biopsy study. Thorax, 58:135-42.
11. Andersson F, Borg S, Jansson SA, et al. 2002. The costs of exacerbations in chronic obstructive pulmonary disease (COPD). Respir Med, 96:700-8.
12. Angrill J, Agusti C, De Celis R, et al. 2001. Bronchial inflammation and colonization in patients with clinically stable bronchiectasis. Am J Respir Crit Care Med, 164:1628-32.
13. Anthonisen N, Manfreda J, Warren C, et al. 1987. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Int Med, 106:196-204.
14. Anzueto A, Rizzo JA, Grossman RF. 1999. The infection-free interval: its use in evaluating antimicrobial treatment of acute exacerbations of chronic bronchitis. Clin Inf Dis, 28:1344-5.
15. Aoshiba K, Nagai A, Konno K. 1995. Erythromycin shortens neutrophil survival by accelerating apoptosis. Antimicrob Agents Chemother, 39:872-7.
16. Ashitani J, Doutsu Y, Taniguchi H, et al. 1992. A case of diffuse panbronchiolitis relieved rapidly by the treatment of roxithromycin (Japanese). J Jpn Assoc Infect Dis, 66:657-8.
17. Bach PB, Brown C, Gelfand SE, et al. 2001. Management of acute exacerbations of chronic obstructive pulmonary disease: a summary and appraisal of published evidence. Ann Intern Med, 134:600-20.
18. Bakri F, Brauer AL, Sethi S, et al. 2002. Systemic and mucosal antibody response to Moraxella catarrhalis after exacerbations of chronic obstructive pulmonary disease. J Infect Dis, 185:632-40.
19. Balter MS, La Forge J, Low DE, et al. 2003. Canadian guidelines for the management of acute exacerbations of acute exacerbations of chronic bronchitis. Can Respir J, 10(Suppl B):3B-32B.
20. Bandi v, Jakubowycz M, Kinyon C, et al. 2003. Infectious exacerbations of chronic obstructive pulmonary disease associated with respiratory viruses and non-typeable Haemophilus influenzae. FEMS Immunol Med Microbiol, 10:69-75.
21. Banerjee D, Honeybourne D, Khair OA. 2004. The effect of oral clarithromycin on bronchial airway inflammation in moderate-to-severe stable COPD: a randomized controlled trial. Treat Respir Med, 3:59-65.
22. Banerjee D, Khair OA, Honeybourne D. 2004. Impact of sputum bacteria on airway inflammation and health status in clinical stable COPD. Eur Respir J, 23:685-91.
23. Barker AF. 2003. Bronchiectasis. New Eng J Med, 346:1383-93.
24. Barnes PJ, Shapiro SD, Pauwels RA. 2003. Chronic obstructive pulmonary disease: molecular and cellular mechanisms. Eur Respir J, 22:672-88.
25. Basyigit I, Yildiz F, Ozkara SK, et al. 2004. The effect of clarithromycin on inflammatory markers in chronic obstructive pulmonary disease: preliminary data. Ann Pharmacother, 38:783-92.
26. Baumann U, Fischer JJ, Gudowius P, et al. 2001. Buccal adherence of Pseudomonas aeruginosa in patients with cystic fibrosis under long-term therapy with azithromycin. Infection, 29:7-11.
27. Beaty CD, Grayston JT, Wang SP, et al. 1991. Chlamydia pneumoniae, strain Twar, infection in patients with chronic obstructive pulmonary disease. Am Rev Respir Dis, 144:1408-10.
28. Black PN, Blasi F, Jenkins CR, et al. 2001. Trial of roxithromycin in subjects with asthma and serological evidence of infection with Chlamydia pneumoniae. Am J Respir Crit Care Med, 164:536-41.
29. Blasi F, Damato S, Cosentini R, et al. 2002. Chlamydia pneumoniae and chronic bronchitis: association with severity and bacterial clearance following treatment. Thorax, 57:672-6.
30. Blasi F, Legnani D, Lombardo VM, et al. 1993. Chlamydia pneumoniae infection in acute exacerbations of COPD. Eur Respir J, 6:19-22.
31. Blasi F, Ewig S, Torres A, et al. 2006. A review of guidelines for antibacterial use in acute exacerbations of chronic bronchitis. Pulm Pharmacol Ther, 19:361-9.
32. Bresser P, Out TA, van Alphen L, et al. 2000. Airway inflammation in nonobstructive and obstructive chronic bronchitis with chronic Haemophilus influenzae airway infection. Am J Respir Crit Care Med, 162:947-52.
33. Caramori G, Adcock I. 2003. Pharmacology of airway inflammation in asthma and COPD. Pulm Pharmacol Ther, 16:247-77.
34. Chin CL, Manzel LJ, Lehman EE, et al. 2005. Haemophilus influenzae from COPD patients with exacerbation induce more inflammation than colonizers. Am J Respir Crit Care Med, 172:85-91.
35. Chodosh S. 2005. Clinical significance of the infection-free interval in the management of acute bacterial exacerbations of chronic bronchitis. Chest, 127:2231-6.
36. Chodosh S, McCarty J, Farkas S, et al. 1998. Randomized, double-blind study of ciprofloxacin and cefuroxime axetil for treatment of acute bacterial exacerbations of chronic bronchitis. The Bronchitis Study Group. Clin Infect Dis, 27:722-9.
37. Christ-Crain M, Jaccard-Stolz D, Bingisser R, et al. 2004. Effect of procalcitonin-guided treatment on antibiotic use and outcome in lower respiratory tract infections: cluster-randomised, single-blinded interventionl trial. Lancet, 363:600-7.
38. Culic O, Erakovic V, Cepelak I, et al. 2002. Azithromycin modulates neutrophil function and circulating inflammatory mediators in healthy human subjects. Eur J Pharmacol.
39. Cymbala AA, Edmonds LC, Bauer MA, et al. 2005. The disease-modifying effects of twice-weekly oral azithromycin in patients with bronchiectasis. Treat Respir Med, 4:117-22.
40. Da6vies G, Wilson R. 2004. Prophylactic antibiotic treatment of bronchiectasis with azithromycin. Thorax, 59:540-1.
41. Desaki M, Okazaki H, Sunazuka T, et al. 2004. Molecular mechanisms of anti-inflammatory action of erythromycin in human bronchial epithelial cells: possible role in the signaling pathway that regulates nuclear factor-κB activation. Antimicrob Agent Chemother, 48:1581-5.
42. Desaki M, Takizawa H, Ohtoshi T, et al. 2000. Erythromycin suppresses nuclear factor-kB and activator protein-1 activation in human bronchial epithelial cells. Biochim Biophys Res Com, 267:124-8.
43. Dev D, Wallace E, Sankaran R, et al. 1998. Value of C-reactive protein measurements in exacerbations of chronic obstructive pulmonary disease. Respir Med, 92:664-7.
44. Devalia JL, Rusznak C, Herdman MJ, et al. 1994. Effect of nitrogen dioxide and sulphur dioxide on airway response of mild asthmatic patients to allergen inhalation. Lancet, 344:1668-71.
45. Di Stefano A, Capelli A, Lusuardi M, et al. 2001. Decreased T lymphocyte infiltration in bronchial biopsies of subjects with severe chronic obstructive pulmonary disease. Clin Exp Allergy, 31:893-902.
46. Di Stefano A, Caramori G, Ricciardolo FLM, et al. 2004. Cellular and molecular mechanisms in chronic obstructive pulmonary disease: an overview. Clin Exp Allergy, 34:1156-67.
47. Di Stefano A, Turato G, Maestrelli P, et al. 1996. Airflow limitation in chronic bronchitis is associated with T-lymphocyte and macrophage infiltration of the bronchial mucosa. Am J Respir Crit Care Med, 153:629-32.
48. DiMango E, Ratner AJ, Bryan R, et al. 1998. Activation of NF-kappaB by adherent Pseudomonas aeruginosa in normal and cystic fibrosis respiratory epithelial cells. J Clin Invest, 101:2598-605.
49. Donaldson GC, Seemungal TA, Bhowmik A, et al. 2002. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax, 57:847-52.
50. Douwes J, Gibson P, Pekkanen J, et al. 2002. Non-eosinophilic asthma: importance and possible mechanisms. Thorax, 57:643-8.
51. Drost EM, Skwarski KM, Sauleda J, et al. 2005. Oxidative stress and airway inflammation in severe exacerbations of COPD. Thorax, 60:293-300.
52. Druss BG, Marcus SC, Olfson M, et al. 2002. The most expensive medical conditions in America. Health Aff (Millwood), 21:105-11.
53. Eller J, Ede A, Schaberg T, et al. 1998. Infective exacerbations of chronic obstructive pulmonary disease. Relation between bacteriologic etiology and lung function. Chest, 113:1542-8.
54. Equi A, Balfour-Lynn IM, Bush A, et al. 2002. Long term azithromycin in children with cystic fibrosis: a randomised, placebo-controlled crossover trial. Lancet, 360:978-84.
55. Evans DJ, Cullinan P, Geddes DM, et al. 2003. Troleandomycin as an oral corticosteroid sparing agent in stable asthma. Cochrane Database Syst Rev, 3.
56. Fagon JY, Chastre J, Trouillet JL, et al. 1990. Characterization of distal bronchial microflora during acute exacerbation of chronic bronchitis: use of the protected specimen brush technique in 54 mechanically ventilated patients. Am Rev Respir Dis, 142:1004-8.
57. Finkelstein R, Fraser RS, Ghezzo H, et al. 1995. Alveolar inflammation and its relation to emphysema in smokers. Am J Respir Crit Care Med, 152:1666-72.
58. Fost DA, Leung DY, Martin RJ, et al. 1999. Inhibition of methylprednisolone elimination in the presence of clarithromycin therapy. J Allergy Clin Immunol, 103:1031-5.
59. Fujii T, Kadota J, Kawakami K, et al. 1995. Long term effect of erythromycin therapy in patients with chronic Pseudomonas aeruginosa infection. Thorax, 50:1246-52.
60. Fujimoto K, Yasuo M, Urushibata K, et al. 2005. Airway inflammation during stable and acutely exacerbated chronic obstructive pulmonary disease. Eur Respir J, 25:640-6.
61. Gaga M, Bentley AM, Humbert M, et al. 1998. Increases in CD4+ T lymphocytes, macrophages, neutrophils and interleukin 8 positive cells in the airways of patients with bronchiectasis. Thorax, 53:685-91.
62. Garcia-Aymerich J, Tobias A, Anto JM, et al. 2000. Air pollution and mortality in a cohort of patients with chronic obstructive pulmonary disease. J Epidemiol Community Health, 54:73-4.
63. Garey KW, Rubinstein I, Gotfried MH, et al. 2000. Long-term clarithromycin decreases prednisone requirements in elderly patients with prednisone-dependent asthma. Chest, 118:1826-7.
64. Gillis RJ, Iglewski BH. 2004. Azithromycin retards Pseudomonas aeruginosa biofilm formation. J Clin Microbiol, 42:5842-5.
65. Gomez J, Baños V, Simarro E, et al. 2000. Estudio prospective y comparative (1994-1998) sobre la influencia del tratamiento corto profilactico con azitromicina en pacientes con EPOC evolucionada. Rev Esp Quimioterap, 13:379-83.
66. Gompertz S, O'Brien C, Bayley DL, et al. 2001. Changes in bronchial inflammation during acute exacerbations of chronic bronchitis. Eur Respir J, 17:1112-19.
67. Gonzales R, Malone DC, Maselli JH, et al. 2001. Excessive antibiotic use for acute respiratory infections in the United States. Clin Inf Dis, 33:757-62.
68. Greenberg SB. 2002. Viral respiratory infections in elderly patients and patients with chronic obstructive pulmonary disease. Am J Med, 112 (6A):28S-32S.
69. Grumelli S, Corry DB, Song LZ, et al. 2004. An immune basis for lung parenchymal destruction in chronic obstructive pulmonary disease and emphysema. PLOS Med, 1:75-83.
70. Gulsvik A. 2001. The global burden and impact of chronic obstructive pulmonary disease worldwide. Monaldi Arch Chest Dis, 56:261-4.
71. Gump DW, Phillips CA, Forsyth BR. 1976. Role of infections in chronic bronchitis. Am Rev Respir Dis, 113:465-73.
72. Halbert RJ, Isonaka S, George D, et al. 2003. Interpreting COPD prevalence estimamtes: what is the true burden of disease? Chest, 123:1684-92.
73. Halpern MT, Higashi MK, Bakst AW, et al. 2003. The economic impact of acute exacerbations of chronic bronchitis in the United States and Canada: A literature review. J Manages Care Pharm, 9:353-9.
74. Halpern MT, Stanford RH, Borker R. 2003. The burden of COPD in the USA: results from the Confronting COPD survey. Respir Med, 97 (Suppl C):S81-9.
75. Hamelin ME, Cote S, Laforge J, et al. 2005. Human metapneumo-virus infection in adults with community-acquired pneumonia and exacerbation of chronic obstructive pulmonary disease. Clin Infect Dis, 41:498-502.
76. Hashimoto N, Kawabe T, Hara T, et al. 2001. Effect of erythromycin on matrix metalloproteinase-9 and cell migration. J Lab Clin Med, 137:176-83.
77. Haydon RC, Thelin JW, Davis WE. 1984. Erythromycin ototoxicity: analysis and conclusions based on 22 case reports. Otolaryngol Head Neck Surg, 92:678-84.
78. Hill AT, Campbell EJ, Bayley DL, et al. 1999. Evidence for excessive bronchial inflammation during an acute exacerbation of chronic obstructive pulmonary disease in patients with a1-antitrypsin deficiency (PiZ). Am J Respir Crit Care Med, 160:1968-75.
79. Hill AT, Campbell EJ, Hill SL, et al. 2000. Association between airway bacterial load and markers of airway inflammation in patients with stable chronic bronchitis. Am J Med, 109:288-95.
80. Hiratsuka T, Mukae H, Lliboshi H, et al. 2003. Increased concentration of human β-defensins in plasma and bronchoalveolar lavage fluid of patients with diffuse panbronchiolitis. Thorax, 58:425-30.
81. Hirschmann JV. 2000. Do Bacteria cause exacerbations of COPD? Chest, 118:193-203.
82. Ho PL, Chan KN, Ip MSM, et al. 1998. The effect of Pseudomonas aeruginosa infection on clinical parameters in steady-state bronchiectasis. Chest, 114:1594-8.
83. Hogg JC, Chu F, Utokaparch S, et al. 2004. The nature of small-airway obstruction in chronic obstructive pulmonary disease. N Eng J Med, 350:2645-53.
84. Homma H, Yamanaka A, Tanimoto S. 1983. Diffuse panbronchiolitis: a disease of the transitional zone of the lung. Chest, 83:63-9.
85. Hurst JR, Perera WR, Wilkinson TMA, et al. 2006. Systemic, upper and lower airway inflammation at exacerbation of COPD. Am J Respir Crit Care Med, 173:71-78.
86. Iannini PB. 2002. Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval. Expert Opin Drug Saf, 1:121-8.
87. Ichikawa Y, Ninomiya H, Koga H, et al. 1993. Erythromycin reduces neutrophils and neutrophil-derived elastolytic-like activity in the lower respiratory tract of bronchiolitis patients. Am Rev Respir Des, 147:1064-5.
88. Ichimiya T, Takeoka K, Hiramatsu K, et al. 1996. The influence of azithromycin on the biofilm formation of Pseudomonas aeruginosa in vitro. Chemotherapy, 42:186-91.
89. Imamura Y, Higashiyama Y, Tomono K, et al. 2005. Azithromycin exhibits bactericidal effects on Pseudomonas aeruginosa through interaction with the outer membrane. Antimicrob Agent Chemother, 49:1377-80.
90. Imamura Y, Yanagihara K, Mizuta Y, et al. 2004. Azithromycin inhibits MUC5AC production induced by the Pseudomonas aeruginosa auto-inducer N-(3-Oxododecanoyl) homoserine lactone in NCI-H292 cells. Antimicrob Agent Chemother, 48:3457-61.
91. Inamura K, Ohta N, Fukase S, et al. 2000. The effects of erythromycin on human peripheral neutrophil apoptosis. Rhinology, 38:124-9.
92. Inoue M, Okamoto R, Okubo T, et al. 1992. Comparative in-vitro activity of RP 59500 against clinical bacterial isolates. J Antimicrob Chemother, 30 (Suppl A):45-51.
93. Ishimatsu Y, Kadota J, Iwashita T, et al. 2004. Macrolide antibiotics induce apoptosis of human peripheral lymphocytes in vitro. Int J Antimicrob Agents, 24:247-53.
94. Ishizawa K, Suzuki T, Yamaya M, et al. 2005. Erythromycin increases bactericidal activity of surface liquid in human airways epithelial cells. Am J Physiol Lung Mol Physiol, 289:L565-73.
95. Ito K, Ito M, Elliott WM, et al. 2005. Decreased histone deacetylase activity in chronic obstructive pulmonary disease. N Eng J Med, 352:1967-76.
96. Jaffe A, Bush A. 2001. Anti-inflammatory effects of macrolides in lung disease. Pediatric Pulmonology, 31:464-73.
97. Jaffe A, Francis J, Rosenthal M, et al. 1998. Long-term azithromycin may improve lung function in children with cystic fibrosis. Lancet, 351:420.
98. Jain R, Danziger LH. 2004. The macrolide anbiotics: a pharmacokinetic and pharmacodynamic overview. Curr Pharm Des, 10:3045-53.
99. Johnston SL. 2005. Overview of virus-induced airway disease. Proc Am Thorac Soc, 2:150-6.
100. Kadota J, Mukae H, Ishii H, et al. 2003. Long-term efficacy and safety of clarithromycin treatment in patients with diffuse panbronchiolitis. Resp Med, 97:844-50.
101. Kadota J, Mukae H, Tomono K, et al. 2001. High concentrations of β-chemokines in BAL fluid of patients with diffuse panbronchiolitis. Chest, 120:602-7.
102. Kadota J, Sakito O, Kohno S, et al. 1993. A mechanism of erythromycin treatment in patients with diffuse panbronchiolitis. Am Rev Respir Dis, 147:153-9.
103. Kadota JI, Mizunoe S, Kishi K, et al. 2005. Antibiotic-induced apoptosis in human activated peripheral lymphocytes. Int J Antimicrob Agent, 25:216-20.
104. Kamoi H, Kurihara N, Fujiwara H, et al. 1995. The macrolide antibacterial roxithromycin reduces bronchial hyperresponsiveness and superoxide anion production by polymorphonuclear leukocytes in patients with asthma. J Asthma, 32:191-7.
105. Kanai K, Asano K, Hisamitsu T, et al. 2004. Suppression of matrix metalloproteinase production from nasal fibroblasts by macrolide antibiotics in vitro. Eur Respir J, 23:671-8.
106. 1 decline in current smokers but not ex-smokers with mild chronic obstructive pulmonary disease. Am J Respir Crit Care Med, 164:358-64.
107. Karnak D, Beng-sun S, Beder S, et al. 2001. Chlamydia pneumoniae infection and acute exacerbation of chronic obstructive pulmonary disease (COPD). Respir Med, 95:811-16.
108. Kasahara K, Kita E, Maeda K, et al. 2005. Macrolide resistance of Streptococcus pneumoniae isolated during long-term macrolide therapy: difference between erythromycin and clarithromycin. J Infect Chemother, 11:112-4.
109. Kawamura-Sato K, Iinuma Y, Hasegawa T, et al. 2000. Effect of subinhibitory concentrations of macrotides on expression of flagellin in Pseudomonas aeruginosa and Proteus mirabilis. Antimicrob Agent Chemother, 44:2869-72.
110. Keicho N, Kudoh S, Yotsumoto H, et al. 1994. Erythromycin promotes monocyte to macrophage differentiation. J Antibiot (Tokyo), 47:80-9.
111. Kemeny DM, Vyas B, Vukmanovic-Stejic M, et al. 1999. CD8(+) T cell subsets and chronic obstructive pulmonary disease. Am J Respir Crit Care Med, 160:S33-7.
112. Khan AA, Slifer TR, Araujo FG, et al. 1999. Effect of clarithromycin and azithromycin on production of cytokines by human monocytes. Int J Antimicrob Agent, 11:121-32.
113. Khan TZ, Wagener JS, Bost T, et al. 1995. Early pulmonary inflammation in infants with cystic fibrosis. Am J Respir Crit Care Med, 151:1075-82.
114. Kikuchi T, Hagiwara K, Honda Y, et al. 2002. Clarithromycin suppresses lipopolysaccharide-induced interteukin-8 production by human monocytes through AP-1 and NF-κB transcription factors. J Antimicrob Chemother, 49:745-55.
115. Klugman KP, Lonks JR. 2005. Hidden epidemic of macrolide-resistant pneumococci. Emer Inf Dis, 11:802-7.
116. Kobayashi H, Takeda H, Sakayori S, et al. 1995. Study on azithromycin in treatment of diffuse panbronchiolitis (English abstract). J Jpn Assoc Infect Dis, 69:711-22.
117. Kobayashi H. 1995. Biofilm disease: its clinical manifestation and therapeutic possibilities of macrolides. Am J Med, 99:26S-30S.
118. Koh YY, Lee MH, Sun YH, et al. 1997. Effect of roxithromycin on airway responsiveness in children with bronchiectasis: a double-blind, placebo-controlled study. Eur Respir J, 10:994-9.
119. Kohyama T, Takizawa H, Kawasaki S, et al. 1999. Fourteen-member macrolides inhibit interleukin-8 release by human eosinophils from atopic donors. Antimicrob Agent Chemother, 43:907-11.
120. Kostadima E, Tsiodras S, Alexopoulos EK, et al. 2004. Clarithromycin reduces the severity of bronchial hyperresponsiveness in patients with asthma. Eur Respir J, 23:714-17.
121. Koyama H, Geddes DM. 1997. Erythromycin and diffuse panbronhiolitis. Thorax, 52:915-18.
122. Kraft M, Cassell GH, Pak J, et al. 2002. Mycoplasma pneumoniae and Chlamydia pneumoniae in asthma. Effect of clarithromycin. Chest, 121:1782-8.
123. Kudoh S, Azuma A, Yamamoto M, et al. 1998. Improvement of survival in patients with diffuse panbronchiolitis treated with low-dose erythromycin. Am J Respir Crit Care Med, 157:1829-32.
124. Kudoh S, Kimura K, Uetake K, et al. 1984. Abstract of annual meeting. Jpn J Thorac Dis, 22:254.
125. Kudoh S, Uetake T, Hagiwara K, et al. 1987. Clinical effect of low-dose long-term erythromycin chemotherapy on diffuse panbronchiolitis (English Abstract). Jpn J Thorac Dis, 25:632-42.
126. Labro MT. 2004. Cellular and molecular effects of macrolides on leukocyte function. Curr Pharm Des, 10:3067-80.
127. LaForce CF, Szefler SJ, Miller MF, et al. 1983. Inhibition of methylprednisolone elimination in the presence of erythromycin therapy. J Allergy Clin Immunol, 72:34-9.
128. Lieberman D, Ben-Yaakov M, Lazarovich Z, et al. 2001. Chlamydia pneumoniae infection in acute exacerbations of chronic obstructive pulmonary disease: analysis of 250 hospitalizations. Eur J Clin Microbiol Infect Dis, 20:698-704.
129. Lode H, Eller J, Linnhoff A, et al. 2004. Levofloxacin versus clarithromycin in COPD exacerbation: focus on exacerbation-free interval. Eur Respir J, 24:947-53.
130. Majo J, Ghezzo H, Cosio MG. 2001. Lymphocyte population and apoptosis in the lungs of smokers and their relation to emphysema. Eur Respir J, 17:946-53.
131. Mannino DM, Homa DM, Akinbami LJ, et al. 2002. Chronic obstructive pulmonary disease surveillance - United States, 1971-2000. MMWR, 51:1-16.
132. Martinez FJ. 2004. Acute bronchitis: state of the art diagnosis and therapy. Compr Ther, 30:55-69.
133. Martinez FJ, Grossman RF, Zadeikis N, et al. 2005. Patient stratification in the management of acute bacterial exacerbation of chronic bronchitis: the role of levofloxacin 750 mg. Eur Respir J, 2005.
134. Martinez FJ, Simon RH. 2004. Clinical implications of macrolide therapy in chronic sinopulmonary diseases. Curr Pharm Des, 10.
135. McCrory DC, Brown C, Gelfand SE, et al. 2001. Management of acute exacerbations of COPD. A summary and appraisal of published evidence. Chest, 119:1190-209.
136. McGuire A, Irwin DE, Penn P, et al. 2001. The excess of acute exacerbations of chronic bronchitis in patients aged 45 and older in England and Wales. Value Health, 4:370-5.
137. Milberg P, Eckardt L, Bruns HJ, et al. 2002. Diveregent proarrhythmic potential of macrolide antibiotics despite similar QT prolongation: fast phase 3 repolarization prevents early afterdepolarizations and torsade de pointes. J Pharmacol Exp Therapeut, 303:218-25.
138. Miravitlles M, Espinosa C, Fernandez-Laso E, et al. 1999. Relationship between bacterial flora in sputum and functional impairment in patients with acute exacerbations of COPD. Chest, 116:40-6.
139. Miravitlles M, Ferrer M, Pont A, et al. 2004. Effect of exacerbations on quality of life in patients with chronic obstructive pulmonary diseasee: a 2 year follow up study. Thorax, 59:387-95.
140. Miravitlles M, Llor C, Naberan K, et al. 2004. Effect of various antimicrobial regimens on the clinical course of exacerbations of chronic bronchitis and chronic obstructive pulmonary disease in primary care. Clin Drug Invest, 24:63-72.
141. Miravitlles M, Torres A. 2004. No more equivalence trials for antibiotics in exacerbations of COPD, please. Chest, 125:811-13.
142. Miravitlles M, Murio C, Guerrero T, et al. 2002. Pharmacoeconomic Evaluation of Acute Exacerbations of Chronic Bronchitis and COPD*. Chest, 121:1449-1455.
143. Miyatake H, Taki F, Taniguchi H, et al. 1991. Erythromycin reduces the severity of bronchial hyperresponsiveness in asthma. Chest, 99:670-3.
144. Mogulkoc N, Karakurt S, Isalska B, et al. 1999. Acute purulent exacerbation of chronic obstructive pulmonary disease and Chlamydia pneumoniae infection. Am J Respir Crit Care Med, 160:349-53.
145. Molinari G, Guzman CA, Pesce A, et al. 1993. Inhibition of Pseudomonas aeruginosa virulence factors by subinhibitory concentrations of azithromycin and other macrolide antibiotics. J Antimicrob Chemother, 31:681-8.
146. Monso E, Garcia-Aymerich J, Soler N, et al. 2003. Bacterial infection in exacerbated COPD with changes in sputum characteristics. Epidemiol Infect, 131:799-804.
147. Monso E, Ruiz J, Rosell A, et al. 1995. Bacterial infection in chronic obstructive pulmonary disease: A study of stable and exacerbated outpatients using the protected specimen brush. Am J Respir Crit Care Med, 152:1316-1320.
148. Motojima S, Adachi T, Manaka K, et al. 1996. Eosinophil peroxidase stimulates the release of granulocyte-macrophage colony-stimulating factor from bronchial epithelial cells. J Allergy Clin Immunol, 98:S216-23.
149. Mukae H, Kadota J, Kohno S, et al. 1995. Increase in activated CD8+ cells in bronchoalveolar lavage fluid in patients with diffuse panbronchiolitis. Am J Respir Crit Care Med, 152:613-8.
150. Murphy TF, Brauer AL, Grant BJB, et al. 2005. Moraxella catarrhalis in chronic obstructive pulmonary disease: burden of disease and immune reponse. Am J Respir Crit Care Med.
151. Murphy TF, Sethi S, Niederman MS. 2000. The role of bacteria in exacerbations of COPD. A constructive view. Chest, 118:204-9.
152. Musher DM, Kubitschek KR, Crennan J, et al. 1983. Pneumonia and acute febrile tracheobronchitis due to Haemophilus influenzae. Ann Intern Med, 99:444-50.
153. Nagai A, Shishido H, Yoneda R, et al. 1991. Long-term low-dose administration of erythromycin to patients with diffuse panbronchiolitis. Respiration, 58:145-9.
154. Nagata T, Mukae H, Kadota J, et al. 2004. Effect of erythromycin on chronic respiratory infection caused by Pseudomonas aeruginosa with biofilm formation in an experimental murine model. Antimicrob Agents Chemother, 48:2251-9.
155. Nakamura H, Fujishima S, Inoue T, et al. 1999. Clinical and immunoregulatory effects of roxithromycin therapy for chronic respiratory tract infection. Eur Respir J, 13:1371-9.
156. Nguyen T, Louie SG, Beringer PM, et al. 2002. Potential role of macrolide antibiotics in the management of cystic fibrosis lung disease. Curr Opin Pulm Med, 8:521-8.
157. Niederman MS, McCombs JS, Unger AN, et al. 1999. Treatment cost of acute exacerbations of chronic bronchitis. Clinical Therapeutics, 21:576-591.
158. Nishimura K, Kitaichi M, Izumi T, et al. 1992. Diffuse panbronchiolitis: correlation of high resolution CT and pathologic findings. Radiology, 184:779-85.
159. Niven AS, Argyros G. 2003. Alternate treatments in asthma. Chest, 123:1254-65.
160. Nouira S, Marghli S, Belghith M, et al. 2001. Once daily oral ofloxacin in chronic obstructive pulmonary disease exacerbation requiring mechanical ventilation: a randomised placebo-controlled trial. Lancet, 358:2020-5.
161. O'Brien C, Guest PJ, Hill SL, et al. 2000. Physiological and radiological characterisation of patients diagnosed with chronic obstructive pulmonary disease in primary care. Thorax, 55:635-42.
162. Oda H, Kadota J, Kohno S, et al. 1994. Erythromycin inhibits neutrophil chemotaxis in bronchoalveoli of diffuse panbronchiolitis. Chest, 106:1116-23.
163. Ogawa N, Sugawara Y, Fujiwara Y, et al. 2003. Roxithromycin promotes lymphocyte apoptosis in Dermatophagoides-sensitive asthma patients. Eur J Pharmacol, 474:273-81.
164. Ohno S, Sugiyama Y, Kitamura S. 1993. Clinical effects of low-dose and long-term erythromycin in diffuse panbronchilotis with chronic respiratory failure (Engish Abstract). Jpn J Thorac Dis, 31:1251-6.
165. Ohtoshi T, Takizawa H, Okazaki H, et al. 1998. Diesel exhaust particulates stimulate human airway epithelial cells to produce cytokines relevant to airway inflammation in vitro. J Allergy Clin Immunol, 101:778-85.
166. Oishi K, Sonoda F, Kobayashi A, et al. 1994. Role of interleukin-8 (IL-8) and an inhibitory effect of erythromycin on IL-8 release in the airways of patients with chronic airway diseases. Infect Immun, 62:4145-52.
167. Oishi K, Sonoda F, Kobayashi S, et al. 1994. Role of interleukin-8 (IL-8) and an inhibitory effect of erythromycin on IL-8 release in the airways of patients with chronic airway diseases. Infect Immun, 62:4145-52.
168. Oostenbrink JB, Rutten-van Molken M. 2004. Resource use and risk factors in high-cost exacerbations of COPD. Respir Med, 98:883-91.
169. O'Shaughnessy TC, Ansari TW, Barnes NC, et al. 1997. Inflammation in bronchial biopsies of subjects with chronic bronchitis: inverse relationship of CD8+ T lymphocytes with FEV1. Am J Respir Crit Care Med, 155:852-7.
170. Parker CM, Voduc N, Aaron SD, et al. 2005. Physiological changes during symptom recovery from moderate exacerbations of COPD. Eur Respir J, 26:420-8.
171. Parnham MJ, Culic O, Erakovic V, et al. 2005. Modulation of neutrophil and inflammation markers in chronic obstructive pulmonary disease by short-term azithromycin treatment. Eur J Pharmacol, 517:132-43.
172. Patel IS, Seemungal TAR, Wilks M, et al. 2002. Relationship between bacterial colonisation and the frequency, character, and severity of COPD exacerbations. Thorax, 57:759-64.
173. Pauwels R, Calverley P, Buist AS, et al. 2004. COPD exacerbations: the importance of a standard definition. Respir Med, 98:99-107.
174. Pauwels RA, Buist AS, Calverley PMA, et al. 2001. Committee GOLD Scientific. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop Summary. Am J Respir Crit Care, 163:1256-76.
175. Pechere JC. 2001. New perspectives on macrolide antibiotics. Int J Antimicrob Agents, 18:S93-7.
176. Pela R, Marchesani F, Agostinelli C, et al. 1998. Airways microbial flora in COPD patients in stable clinical conditions and during exacerbations: a bronchoscopic investigation. Monaldi Arch Chest Dis, 53:262-7.
177. Petty TL. 2000. Scope of the COPD Problem in North America. Chest, 117:326S-331S. Pietila MP, Thomas CF. 2003. Inflammation and infection in exacerbations of chronic obstructive pulmonary disease. Sem Resp Inf, 18:9-16.
178. Pletz MW, McGee L, Jorgensen J, et al. 2004. Levofloxacin-resistant invasive Streptococcus pneumoniae in the United States: evidence for clonal spread and the impact of conjugate pneumococcal vaccine. Antimicrob Agents Chemother, 48:3491-7.
179. Qiu Y, Zhu J, Bandi V, et al. 2003. Biopsy neutrophilia, neutrophil chemokine and receptor gene expression in severe exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med, 168:968-75.
180. Reato G, Cuffini AM, Tullio V, et al. 2004. Immunomodulating effect of antimicrobial agents on cytokine production by human polymorphonuclear neutrophils. Int J Antimicrob Agent, 23:150-4.
181. Reichenberger F, Wyser C, Gonon M, et al. 2001. Pulmonary mucosa-associated lymphoid tissue lymphoma in a patient with common variable immunodeficiency syndrome. Respiration, 68:109-12.
182. Rhode G, Wiethege A, Borg I, et al. 2003. Respiratory viruses in
183. Richeldi L, Ferrara G, Fabbri L, et al. 2005. Macrolides for chronic asthma. Cochrane Database Syst Rev, 4.
184. Richman-Eisenstat JBY, Jorens PG, Hebert CA, et al. 1993. Interleukin-8: an important chemoattractant in sputum of patients with chronic inflammatory airway diseases. Am J Physiol, 264:L413-18.
185. Rodrigues-Roisin R. 2000. Toward a consensus definition for COPD exacerbations. Chest, 117:398S-401S.
186. Roland M, Bhowmik A, Sapsford RJ, et al. 2001. Sputum and plasma endothelin-a levels in exacerbations of chronic obstructive pulmonary disease. Thorax, 56:30-5.
187. Rosell A, Monso E, Soler N, et al. 2005. Microbiologic determinants of exacerbation in chronic obstructive pulmonary disease. Arch Intern Mad, 165:891-7.
188. Rubin BK, Druce H, Ramirez OE, et al. 1997. Effect of clarithromycin on nasal mucus properties in healthy subjects and in patients with purulent rhinitis. Am J Respir Crit Care Med, 155:2018-23.
189. Rudell B, Blomberg A, Helleday R, et al. 1999. Bronchoalveolar inflammation after exposure to diesel exhaust: comparison between unfiltered and particulate trap filtered exhaust. Occup Environ Med, 56:527-34.
190. Russell RE, Culpitt SV, DeMatos C, et al. 2002. Release and activity of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 by alveolar macrophages from patients with chronic obstructive pulmonary disease. Am J Respir Cell Mol Biol, 26:602-9.
191. Russell RE, Thorley A, Culpitt SV, et al. 2002. Alveolar macrophage-mediated elastolysis: roles of matrix metalloproteinases, cysteine, and serine proteases. Am J Physiol Lung Cell Mol Physiol, 283:L867-73.
192. Rutgers SR, Postma DS, Hacken NH, et al. 2000. Ongoing airway inflammation in patients with COPD who do not currently smoke. Thorax, 55:12-18.
193. Saetta M, Baraldo S, Corbino L, et al. 1999. CD8+ve cells in the lungs of smokers with chronic obstructive pulmonary disease. Am J Respir Crit Care Med, 160:711-7.
194. Saetta M, Di Stefano A, Maestrelli P, et al. 1993. Activated T-lymphocytes and macrophages in bronchial mucosa of subjects with chronic bronchitis. Am Rev Respir Dis, 147:301-6.
195. Saetta M, Di Stefano A, Turato G, et al. 1998. CD8+ T-lymphocytes in peripheral airways of smokers with chronic obstructive pulmonary disease. Am J Respir Crit Care Med, 157:822-6.
196. Saetta M, Mariani M, Panina-Bordignon P, et al. 2002. Increased expression of the chemokine receptor CXCR3 and its ligand CXCL10 in peripheral airways of smokers with chronic obstructive pulmonary disease. Am J Respir Crit Care Med, 165:1404-9.
197. Saetta M, Turato G, Corbino L, et al. 1997. Mechanisms of damage in COPD. Monaldi Arch Chest Dis, 52:586-8.
198. Saiman L, Marshall BC, Mayer-Hamblett N, et al. 2003. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA, 290:1749-56.
199. Saiman L, Mayer-Hamblett N, Campbell P, et al. 2005. Heterogeneity of treatment response to azithromycin in patients with cystic fibrosis. Am J Respir Crit Care Med, 172:1008-12.
200. Saint S, Bent S, Vittinghoff E, et al. 1995. Antibiotics in chronic obstructive pulmonary disease exacerbations. A meta-analysis. JAMA, 273:957-60.
201. Saint S, Flaherty KR, Abrahamse P, et al. 2001. Acute exacerbations of chronic bronchitis: disease-specific issues that influence the cost-effectiveness of antimicrobial therapy. Clin Ther, 23:499-512.
202. Sakito O, Kadota J, Kohno S, et al. 1996. Interleukin 1β, tumor necrosis factor-α, and interleukin 8 in bronchoalveolar lavage fluid of patients with diffuse panbronchiolitis: a potential mechanism of macrolide therapy. Respiration, 63:42-8.
203. Sawaki M, Mikami R, Mikasa K, et al. 1986. The long term chemotherapy with erythromycin in chronic lower respiratory tract infections - Second report: including cases with Pseudomonas infections (English Abstract). J Jpn Assoc Infect Dis, 60:45-50.
204. Scaglione F, Rossoni G. 1998. Comparative anti-inflammatory effects of roxithromycin, azithromycin and clarithromycin. J Antimicrob Chemother, 41(Suppl B):47-50.
205. Schmier JK, Halpern MT, Higashi MK, et al. 2005. The quality of life impact of acute exacerbations of chronic bronchitis (AECB): A literature review. Qual Life Res, 14:329-47.
206. Seemungal T, Harper-Owen R, Bhowmik A, et al. 2001. Respiratory viruses, symptoms, and inflammatory markers in acute exacerbations and stable chronic obstructive pulmonary disease. Am J Respir Crit Care Med, 164:1618-1623.
207. Seemungal TA, Wedzicha JA, MacCallum PK, et al. 2002. Chlamydia pneumoniae and COPD exacerbation. Thorax, 57:1087-8, author reply 1088-9.
208. Seemungal TAR, Donaldson GC, Bhowmik A, et al. 2000. Time course and recovery of exacerbations in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med, 161:1608-13.
209. Sethi S. 1999. Infectious exacerbations of chronic bronchitis: diagnosis and management. J Antimicrob Chemother, 43(Suppl A):97-105.
210. Sethi S. 2000. Infectious etiology of acute exacerbations of chronic bronchitis. Chest, 117:380S-385S.
211. Sethi S. 2004. Bacteria in exacerbations of chronic obstructive pulmonary disease. Phenomenon or epiphenomenon? Proc Am Thorac Soc, 1:109-14.
212. Sethi S, Evans N, Grant BJB, et al. 2002. New strains of bacteria and exacerbations of chronic obstructive pulmonary disease. New Eng J Med, 347:465-71.
213. Sethi S, Murphy TF. 2001. Bacterial infection in chronic obstructive pulmonary disease in 2000: a state-of-the-art review. Clin Microbiol Rev, 14:336-63.
214. Shapiro SD, Ingenito EP. 2005. The pathogenesis of chronic obstructive pulmonary disease. Advances in the past 100 years. Am J Respir Cell Mol Biol, 32:367-72.
215. Shimizu T, Kato M, Mochizuki H, et al. 1994. Roxithromycin reduces the degree of bronchial hyperresponsiveness in children with asthma. Chest, 106:458-61.
216. Shimizu T, Shimizu S, Hattori R, et al. 2003. In vivo and in vitro effects of macrolide antibiotics on mucus secretion in airway epithelial cells. Am J Respir Crit Care Med, 168:581-7.
217. Shoji T, Yoshida S, Sakamoto H, et al. 1999. Anti-inflammatory effect of roxithromycin in patients with aspirin-intolerant asthma. Clin Exp All, 29:950-6.
218. Shryock TR, Mortensen JE, Baumholtz M. 1998. The effects of macrolides on the expression of bacterial virulence mechanisms. J Antimicrob Chemother, 41:505-12.
219. Snow V, Lascher S, Mottur-Pielson C. 2001. Evidence base for management of acute exacerbations of chronic obstructive pulmonary disease. Ann Intern Med, 134:595-9.
220. Soler N, Ewig S, Torres A, et al. 1999. Airway inflammation and bronchial microbial patterns in patients with stable chronic obstructive pulmonary disease. Eur Respir J, 14:1015-22.
221. Soler N, Torres A, Ewig S, et al. 1998. Bronchial microbial patterns in severe exacerbations of chronic obstructive pulmonary disease (COPD) requiring mechanical ventilation. Am J Respir Crit Care Med, 157:1498-1505.
222. Southern KW, Barker PM, Solis A. 2005. Macrolide antibiotics for cystic fibrosis. Cochrane Database Syst Rev, 4.
223. Spencer S, Jones PW, for the GLOBE Study Group. 2003. Time course of recovery of health status following an infective exacerbation of chronic bronchitis. Thorax, 58:589-93.
224. Stevenson NJ, Costello PR, Calverley PMA. 2005. Lung mechanics and dyspnea during exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med, 172:1510-16.
225. Stockley RA, O'Brien C, Pye A, et al. 2000. Relationship of sputum color to nature and outpatient management of acute exacerbations of COPD. Chest, 117:1638-45.
226. Stoller JK. 2002. Acute exacerbations of chronic obstructive pulmonary disease. N Eng J Med, 346:988-94.
227. Stott EJ, Grist NR, Eadie MB. 1968. Rhinovirus infections in chronic bronchitis: isolation of eight possible new rhinovirus serotypes. J Med Microbiol, 1:109-17.
228. Strassels SA, Smith DH, Sullivan SD, et al. 2001. The costs of treating COPD in the United States. Chest, 119:344-52.
229. Sunyer J, Saez M, Murillo C, et al. 1993. Air pollution and emergency room admissions for chronic obstructive pulmonary disease: a 5-year study. Am J Epidemiol, 137:701-5.
230. Sunyer J, Schwartz J, Tobias A, et al. 2000. Patients with chronic obstructive pulmonary disease are at increased risk of death associated with urban particle air pollution: a case-crossover analysis. Am J Epidemiol, 151:50-6.
231. Sutherland ER, Martine RJ. 2003. Airway inflammation in chronic obstructive pulmonary disease: comparisons with asthma. J Allergy Clin Immunol, 112:819-27.
232. Suzaki H, Asano K, Ohki S, et al. 1999. Suppressive activity of a macrolide antibiotic, roxithromycin, on pro-inflammatory cytokine production in vitro and in vivo. Mediators Inflamm, 8:199-204.
233. Suzuki T, Yanai M, Yamaya M, et al. 2001. Erythromycin and common cold in COPD. Chest, 120:730-3.
234. Swanson DJ, Sung RJ, Fine MJ, et al. 1992. Erythromycin ototoxicity: prospective assessment with serum concentrations and audiograms in a study of patients with pneumonia. Am J Med, 92:61-8.
235. Tagaya E, Tamaoki J, Kondo M, et al. 2002. Effect of a short course of clarithromycin therapy on sputum production in patients with chronic airway hypersecretion. Chest, 122:213-18.
236. Takaki M, Ushikai M, Deguchi K, et al. 2003. Interleukin-8 expression by human adenoidal fibroblasts. Laryngoscope, 113:1378-85.
237. Takeda H, Miura H, Kawahira M, et al. 1989. Long-term administration study on TE-031 (A-56268) in treatment of diffuse panbronchiolitis (English Abstract). J Jpn Assoc Infect Dis, 63:71-8.
238. Takeoka K, Ichimiya T, Yamasaki T, et al. 1998. The in vitro effect of macrolides on the interaction of human polymorphonuclear leukocytes with Pseudomonas aeruginosa in biofilm. Chemotherapy, 44:190-7.
239. Takizawa H, Desaki M, Ohtoshi T, et al. 1997. Erythromycin modulates IL-9 expression in normal and inflammed human bronchial epithelial cells. Am J Respir Crit Care Med, 156:266-71.
240. Tamaoki J, Takeyama K, Tagaya E, et al. 1995. Effect of clarithromycin on sputum production and its rheological properties in chronic respiratory tract infections. Antimicrob Agent Chemother, 39:1688-90.
241. Tan WC, Xiang X, Qiu D, et al. 2003. Epidemiology of respiratory viruses in patients hospitalized with near-fatal asthma, acute exacerbations of asthma, or chronic obstructive pulmonary disease. Am J Med, 115:272-7.
242. Tateda K, Comte R, Pechere JC, et al. 2001. Azithromycin inhibits quorum sensing in Pseudomonas aeruginosa. Antimicrob Agents Chemother, 45:1930-3.
243. Traves SL, Donnelly LE. 2005. Chemokines and their receptors as targets for the treatment of COPD. Curr Respir Med Rev, 1:15-32.
244. Trulock EP, Edwards LB, Taylor DO, et al. 2003. The Registry of the International Society for Heart and Lung Transplantation: Twentieth official adult lung and heart-lung transplant report - 2003. J Heart Lung Trans, 22:625-35.
245. Tsai WC, Rodriguez ML, Young KS, et al. 2004. Azithromycin blocks neutrophil recruitment in Pseudomonas endobronchial infection. Am J Respir Crit Care Med, 170:1331-9.
246. Tsai WC, Standiford TJ. 2004. Immunomodulatory effects of macrolides in the lung: lessons from in-vitro and in-vivo models. Curr Pharm Des, 10:3081-93.
247. Tsang KW, Chan KN, Ho PL, et al. 2000. Sputum elastase in steady-state bronchiectasis. Chest, 117:420-6.
248. Tsang KW, Ng P, Ho PL, et al. 2003. Effects of erythromycin on Pseudomonas aeruginosa adherence to collagen and morphology in vitro. Eur Respir J, 21:401-6.
249. Tsang KWT, Ho PI, Chan KN, et al. 1999. A pilot study of low-dose erythromycin in bronchiectasis. Eur Resp J, 13:361-4.
250. Tsoumakidou M, Tzanakis N, Chrysofakis G, et al. 2005. Nitrosative stress, hemo oxygenase-1 expression and airway inflammation during severe exacerbations of COPD. Chest, 127:1911-8.
251. Turato G, Zuin R, Miniati M, et al. 2002. Airway inflammation in severe chronic obstructive pulmonary disease: relationship with lung function and radiologic emphysema. Am J Respir Crit Care Med, 166:105-10.
252. Vanderkooi OG, Low DE, Green K, et al. 2005. Predicting antimicrobial resistance in invasive pneumococcal infections. Clin Inf Dis, 40:1288-97.
253. Villagrasa V, Berto L, Cortijo J, et al. 1997. Effects of erythromycin on chemoattractant-activated human polymorphonuclear leukocytes. Gen Pharmac, 29:605-9.
254. Wagner T, Soong S, Sokol S, et al. 2005. Effects of azithromycin on clinical isolates of Pseudomonas aeruginosa from cystic fibrosis patients. Chest, 128:216-20.
255. Wallace MR, Miller LK, Nguyen MT, et al. 1994. Ototoxicity with azithromycin. Lancet, 343:241.
256. Ward MM, Javitz HS, Smith WM, et al. 2000. Direct medical cost of chronic obstructive pulmonary disease in the U.S.A. Resp Med, 94:1123-9.
257. Wedzicha JA. 2000. The heterogeneity of chronic obstructive pulmonary disease. Thorax, 5:631-2.
258. Wedzicha JA. 2002. Exacerbations. Etiology and pathophysiologic mechanisms. Chest, 121:136S-41S.
259. Wedzicha JA. 2004. Role of viruses in exacerbations of chronic obstructive pulmonary disease. Proc Am Thorac Soc, 1:115-20.
260. White AJ, Gompertz S, Bayley DL, et al. 2003. Resolution of bronchial inflammation is related to bacterial eradication following treatment of exacerbations of chronic bronchitis. Thorax, 58:680-5.
261. Wilkinson TMA, Donaldson GC, Hurst JR, et al. 2004. Early therapy improves outcomes of exacerbations of chronic obstructive pulmonary disease. Am J Resp Crit Care Med, 169:1298-303.
262. Wilson R. 2005. Treatment of COPD exacerbations: antibiotics. Eur Respir Rev, 14:32-8.
263. Wilson R, Allegra L, Huchon G, et al. 2004. Short-term and Long-term outcomes of moxifloxacin compared to standard antibiotic treatment in acute exacerbations of chronic bronchitis. Chest, 125:953-64.
264. Wilson R, Kubin R, Ballin I, et al. 1999. Five day moxifloxacin therapy compared with 7 day clarithromycin therapy for the treatment of acute exacerbations of chronic bronchitis. J Antimicrob Chemother, 44:501-13.
265. Wilson R, Schentag JJ, Ball P, et al. 2002. A comparison of gemifloxacin and clarithromycin in acute exacerbations of chronic bronchitis and long-term clinical outcomes. Clin Ther, 24:639-52.
266. Wolter J, Seeney S, Bell S, et al. 2002. Effect of long term treatment with azithromycin on disease parameters in cystic fibrosis: a randomised trial. Thorax, 57:212-6.
267. Woodhead M, Blasi F, Ewig S, et al. 2005. Guidelines for the management of adult lower respiratory tract infections. Eur Respir J, 26:1139-80.
268. Wouters EFM. 2003. Economic analysis of the Confronting COPD survey: an overview of results. Respir Med, 97(Suppl C):S3-14.
269. Wouters EFM. 2005. Local and systemic inflammation in chronic obstructive pulmonary disease. Proc Am Thorac Soc, 2:26-33.
270. Wozniak DJ, Keyser R. 2004. Effects of subinhibitory concentrations of macrolide antibiotics on Pseudomonas aeruginosa. Chest, 125(2 Suppl).
271. Yamamoto M. 1991. Therapeutic effect of erythromycin in patients with DPB-double blind trial (Japanese). Annual report on the study of diffuse disseminated interstitial lung disease, Grant-in-aid from the Ministry of Health and Welfare in Japan.: 18-20.
272. Yamasawa H, Oshikawa K, Ohno S, et al. 2004. Macrolides inhibit epithelial cell-mediated neutrophil survival by modulating granulocyte macrophage colony-stimulating factor release. Am J Respir Cell Mol Biol, 30:569-75.
273. Yasunami J, Hayashi S. 2001. Fourtenn-membered ring macrolides as anti-angiogenic compounds. Anticancer Res, 21:4253-8.
274. Yi K, Sethi S, Murphy TF. 1997. Human immune response to non-typable Haemophilus influenzae in chronic bronchitis. J Infect Dis, 176:1247-52.
275. Zalewska-Kaszubska J, Gorska D. 2001. Anti-inflammatory capabilities of macrolides. Pharmacol Res, 44:451-4.
276. Zhu J, Qiu YS, Majumdar S, et al. 2001. Exacerbations of bronchitis: bronchial eosinophilia and gene expression for interleukin-4, interleukin-5, and eosinophil chemoattractants. Am J Respir Crit Care Med, 164:109-16.